MEDVi GLP 1

Product Details

MEDVi describes a clinician-led process in which an online assessment is followed by provider review, prescription when appropriate, and pharmacy fulfilment. Its website also states that medication is included in the program cost for applicable plans.

What Is MEDVi GLP-1?

MEDVi GLP-1 is a prescription medication program designed to support weight management through access to GLP-1 treatment via telehealth. The current presentation includes semaglutide as an option, with injectable and dissolvable tablet formats for eligible patients. The program combines medical assessment, prescription services, medication fulfilment and ongoing support.

The program is positioned around personalised medical weight management rather than over-the-counter supplementation. MEDVi describes an online evaluation followed by review from licensed healthcare professionals, with a prescription issued when the clinician determines that treatment is appropriate.

Who May Consider MEDVi GLP-1?

MEDVi GLP-1 may be considered by eligible adults seeking a structured, clinician-guided approach to medical weight management. The program can be particularly convenient for people who prefer telehealth consultations, prescription fulfilment and ongoing support through one service.

Eligibility is determined through a medical assessment rather than by the customer alone. Anyone experiencing ongoing or unexplained health symptoms should obtain an appropriate professional medical evaluation and discuss treatment options with a qualified healthcare provider before starting prescription medication.

How May MEDVi GLP-1 Support General Wellness?

Semaglutide belongs to the GLP-1 receptor agonist class. GLP-1 activity is involved in appetite regulation, glucose metabolism and gastrointestinal processes, making this medication class relevant to medically supervised weight-management care.

MEDVi combines medication access with clinician guidance, personalised care and ongoing support. The service describes unlimited appointments, messaging and support as part of its patient-care offering, helping eligible patients communicate with their care team throughout their program.

The FDA-approved semaglutide products have established prescribing information for specific medical uses. Compounded semaglutide supplied through MEDVi should be used according to the individual prescription and instructions provided by the treating clinician and dispensing pharmacy.

Active Ingredients

Semaglutide is the active GLP-1 medication displayed for the MEDVi program and is prescribed at an individually determined dose.

Semaglutide

As a GLP-1 receptor agonist, Semaglutide is involved in appetite regulation, glucose metabolism and gastrointestinal activity. Within the MEDVi program, it is prescribed at an individually determined dose based on the individual’s needs. The exact compounded concentration and prescribed amount are not publicly disclosed by MEDVi.

Potential Benefits

• Supports a structured medical weight-management plan: May be used as part of a comprehensive approach to weight management under appropriate clinical supervision and guidance.
• Provides access to semaglutide when clinically appropriate: Semaglutide may be prescribed following an assessment to determine whether it is suitable for the individual’s health needs and weight-management goals.
• Supports personalised prescribing through clinician assessment: Treatment can be tailored based on an individual’s medical history, current health status, treatment needs, and clinician evaluation.
• Includes ongoing telehealth communication and care support: Provides convenient access to healthcare professionals for follow-up, treatment guidance, and ongoing support throughout the programme.
• Offers convenient medication fulfilment and direct shipping: Medication fulfilment and delivery services can make it easier for eligible patients to receive their prescribed treatment conveniently at home.

MEDVi describes its program as combining medication with personalised care, provider guidance and ongoing support.

Important Limitations

• The exact compounded formulation may vary by dispensing pharmacy.
• Specific concentration and inactive ingredients are provided with the dispensed prescription rather than publicly listed on the general program page.
• Prescription eligibility and dosing remain under the direction of the treating clinician.

How to Use?

MEDVi GLP-1 comes in injectable and dissolvable tablet forms, depending on the medication selected and prescribed by the clinician.

• Use the exact dose and schedule provided by the prescribing clinician.
• Follow the medication-specific instructions supplied by the dispensing pharmacy.
• Do not change the prescribed amount or frequency without speaking with the healthcare provider.
• Follow the pharmacy’s instructions for administration, storage and handling.
• Keep the medication in accordance with the storage instructions supplied with the dispensed prescription.

MEDVi’s public website describes the injection option as once weekly and the tablet option as one dissolvable tablet per day, while individual prescriptions and compounded formulations should be followed exactly as dispensed.

Warnings and Precautions

• Prescription eligibility should be determined through the MEDVi clinical assessment and prescribing process.
• Discuss pregnancy, plans for pregnancy or breastfeeding with the prescribing healthcare professional before treatment.
• Tell the clinician about all prescription medicines, over-the-counter medicines and supplements currently being used.
• Patients with existing medical conditions should provide complete and accurate medical information during the assessment.
• Do not use semaglutide if you have a known serious hypersensitivity to semaglutide or an ingredient in the prescribed formulation.
• Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 for FDA-approved semaglutide products.
• Inform healthcare professionals about planned surgery or procedures because GLP-1 medicines may affect gastric emptying and have implications around anesthesia or deep sedation.
• Keep prescription medication secured and follow the dispensing pharmacy’s storage instructions.

Possible Side Effects and Interactions

Semaglutide can cause gastrointestinal effects such as nausea, diarrhea, vomiting, constipation and abdominal discomfort. Other reported effects with FDA-approved semaglutide products include headache, fatigue, dizziness and dyspepsia.

Semaglutide can delay gastric emptying and may affect absorption of some oral medicines. People taking prescription medication or managing a medical condition should discuss potential interactions with their healthcare professional or pharmacist before use.

Manufacturing and Quality Information

MEDVi states that it works with multiple U.S. pharmacy providers to fulfil compounded GLP-1 medications and that its team communicates with pharmacy providers regarding product availability, shipping and medication testing information. This approach allows the program to coordinate medication fulfilment through its pharmacy network while providing patients with relevant updates about their prescriptions.

The specific dispensing pharmacy, manufacturing location, GMP documentation, certificate of analysis, third-party testing documentation and inactive-ingredient profile are not publicly disclosed as universal specifications for the MEDVi compounded medication. These details may therefore vary depending on the pharmacy fulfilling an individual prescription and should be confirmed with MEDVi or the dispensing pharmacy when applicable.

Pros

• Prescription-based clinician assessment process with professional review.
• Injectable and dissolvable tablet options displayed for treatment.
• Personalised care with ongoing provider guidance.
• Medication fulfilment through associated pharmacy providers.
• Ongoing telehealth support and convenient messaging.
• Free shipping with the current introductory offer.

MEDVi describes 24/7 access to support, unlimited appointments and messaging, together with direct medication shipping for eligible patients.

Cons

• Exact compounded formulation depends on the dispensing pharmacy.
• Individual dose and concentration are determined by the prescriber.
• Standard Supplement Facts information is not applicable to this prescription medication.
• Eligibility is subject to clinical assessment.

Pricing and Money-Back Guarantee

MEDVi currently presents introductory semaglutide pricing with medication, clinical services and shipping included in the displayed offer.

• Semaglutide Injections: $179 for the first month, reduced from $299.
• Semaglutide Tablets: $249 for the first month
• Supply: The displayed offer includes 4 weeks of medication.
• Shipping: Free shipping with the current offer.
• Included services: The offer includes doctor consultation, 1:1 medical support, written prescription and medication.
• Subscription: MEDVi’s terms describe subscription services and recurring billing for applicable plans. Cancellation requests generally need to be submitted at least 72 hours before the next billing date.
• Refunds: MEDVi’s current refund policy provides a full refund when a subscription is cancelled within the first 72 hours and no subscription services have been received. A refund is also available when a healthcare provider disqualifies the patient for a medical reason. Prescription medications generally cannot be returned for reuse or resale.

Pricing and availability were checked on August 27, 2026 and may change on the official website.

Pharmacist Note

MEDVi GLP-1 is a prescription medication service, so the prescribed dose and formulation should always be checked against the pharmacy label. Patients should tell their healthcare professional about current medicines, supplements, allergies, pregnancy plans and relevant medical conditions before starting treatment.

Frequently Asked Questions

1. What type of product is MEDVi GLP-1?

MEDVi GLP-1 is a prescription telehealth program that provides clinician-guided access to GLP-1 medication, including semaglutide when appropriate.

2. How should MEDVi GLP-1 be taken?

Use semaglutide exactly as prescribed. The current program displays weekly injectable and daily dissolvable tablet options with pharmacy-specific instructions.

3. How long does one supply last?

The current introductory offer includes four weeks of medication, with future supplies subject to the selected plan.

4. Can it be taken with prescription medication?

Potential interactions are possible, so provide your complete medication list to the prescribing clinician before receiving or using semaglutide.

5. Is it suitable during pregnancy or breastfeeding?

Pregnancy and breastfeeding should be discussed with the prescribing healthcare professional before treatment, as medication suitability depends on individual circumstances.

6. What is the refund period?

Current MEDVi terms allow a full refund within the first 72 hours when no subscription services have been received, subject to stated conditions.

Medical Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional before using a dietary supplement, particularly if you are pregnant, breastfeeding, taking medication or managing a medical condition.

Sources and Product Review Information

• Official MEDVi GLP-1 product/program page
• MEDVi cancellation and refund policy.
• MEDVi medical consent and pharmacy-provider information.
• FDA prescribing information for semaglutide products.
• FDA information concerning compounded semaglutide.
• Product information and pricing checked on August 27, 2026.

Affiliate Disclosure: This page may contain affiliate links. If you make a purchase through one of these links, we may earn a commission at no additional cost to you. This does not influence the information presented above, which is based on publicly available product and label information.